Dabrafenib
Orphan DrugFDA Approved
Description
Dabrafenib is a kinase inhibitor indicated for the treatment of anaplastic thyroid cancer with BRAF V600E mutation. It inhibits BRAF V600E kinase, which is involved in cell signaling and growth.
Indications & Therapeutic Use
Anaplastic thyroid cancer with BRAF V600E mutation
Linked Diseases:
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Dabrafenib
| Generic Name | Dabrafenib |
| Brands | 1 brand available |
| Active Ingredient | Dabrafenib mesylate |
| Drug Class | Anaplastic thyroid cancer with BRAF V600E mutation |
| Manufacturer | Novartis |
| Dosage Forms | Capsule |
| Medical Code | L01EC01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes